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Abstract
Background: The prevalence of platelet primary secretion defects (PSD) among patients with bleeding diathesis is
unknown. Moreover, there is paucity of data on the determinants of bleeding severity in PSD patients.
Objective: To determine the prevalence of PSD in patients with clinical bleeding and to study the relationships between the
type of platelet defect and bleeding severity.
Methods: Data on patients referred for bleeding to the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan
(Italy) in the years between 2008 and 2012 were retrieved to study the prevalence of PSD. Demographic, clinical and
laboratory information on 32 patients with a diagnosis of PSD was used to compare patients with or without associated
medical conditions and to investigate whether or not the type and extension of platelet defects were associated with the
bleeding severity score (crude and age-normalized) or with the age at first bleeding requiring medical attention.
Results: The estimated prevalence of PSD among 207 patients with bleeding diathesis and bleeding severity score above 4
was 18.8% (95% confidence interval [CI]: 14.1–24.7%). Patients without associated medical conditions had earlier age of first
bleeding (18 vs 45 years; difference: -27 years; 95% CI: -46 to -9 years) and different platelet functional defect patterns
(Fisher’s exact test of the distribution of patterns, P = 0.007) than patients with accompanying medical conditions. The type
and extension of platelet defect was not associated with the severity of bleeding.
Conclusions: PSD is found in approximately one fifth of patients with clinical bleeding. In patients with PSD, the type and
extension of laboratory defect was not associated with bleeding severity.
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Introduction
Platelet primary secretion defects (PSD) are defined by reduced
primary platelet granule secretion upon stimulation by different
platelet aggregation agonists [1]. PSD often results in bleeding
tendency, which is usually mild to moderate albeit asymptomatic
patients have been described [2–4]. The type of laboratory defect
is heterogeneous, consisting of reduced aggregation upon stimu-
lation by one single or multiple agonists and reduced response only
to low or also to high concentrations of the agonists [5]. PSD may
present as an isolated condition or in association with medical
conditions or diseases such as autoimmune disorders [6,7], liver
disease [8] or cancer [9]. Systematic data on the prevalence,
clinical and laboratory characteristics and determinants of
bleeding severity of PSD are scanty. Studies on these defects
traditionally presented one or few well characterized patients,
perhaps because diagnosing and characterizing PSD requires
labor-intensive laboratory testing and the availability of fresh
samples. More recently, Quiroga et al. investigated the prevalence
of PSD and other hemostatic abnormalities in a cohort of 280
patients referred for mucocutaneous bleeding, yielding a preva-
lence of approximately 19% for PSD [10]. An even higher
percentage of primary secretion defects was found in women with
menorrhagia by Philipp et al, but no distinction regarding nature
and type of the defects was made [11]. The prevalence of PSD in
patients with any type of bleeding and the determinants of
bleeding severity within PSD remain unknown.
With this as a background, we collected data on patients
recently referred to our institution for bleeding diathesis. We used
collected information to study (a) the prevalence of PSD in patients
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with bleeding, (b) the demographic, clinical and laboratory
differences between PSD patients with or without accompanying
medical conditions, and (c) the relationships between platelet
testing results and bleeding severity in patients with PSD.
Methods
Patients
Patients with bleeding or hemostatic testing abnormalities are
referred to the general hematology or to the von Willebrand
disease/rare bleeding disorder outpatient clinics of the Angelo
Bianchi Bonomi Hemophilia and Thrombosis Center, Milan
(Italy) where they undergo a first clinical visit with collection of
detailed medical history (including pharmacological anamnesis,
individual and familial history of bleeding and bleeding severity
score [BSS] compilation as described by Tosetto et al. [12,13]). A
copy of the questionnaire used to compile BSS is in Table S1.
Patients also undergo blood collection for first level diagnostic
tests, which include complete blood count, measurement of
prothrombin time, activated thromboplastin time, von Willebrand
factor (VWF) antigen, and VWF ristocetin cofactor activity [14].
Patient with elevated BSS (i.e. a score of 4 or more) and normal
testing are then referred to the platelet disorder clinic for platelet
functional testing.
For this study, patients seen at the general hematology and at
the von Willebrand and rare-bleeding disorder out-patient clinics
of the Hemophilia and Thrombosis Center in the time period
between January 2008 and March 2012 were screened for
inclusion. Patients were included in the study if they matched
the following criteria: (a) they were referred for diagnostic workup
following a bleeding episode or for hemostatic testing abnormal-
ities; (b) at their first visit to the center they were found to have
clinical history of bleeding, with a BSS equal or above 4. The
rationale of using a cutoff of BSS of 4 or above to define abnormal
bleeding tendency relies on the results of a recent study in 100
apparently healthy individuals, showing that the upper bound of
BSS range in the normal population is 3.6 [15]. Therefore,
patients with a score of 4 or more were deemed to have abnormal
bleeding history.
Definition of PSD and platelet functional testing
Patients were tested for PSD when they had normal platelet
counts at the time of first visit, they were found to have normal
VWF antigen and ristocetin cofactor activity, and they had normal
prothrombin and activated thromboplastin times.
To characterize platelet function, patients underwent the
following examinations: (a) measurement of platelet GpIb/IX/V
and GpIIb/IIIa surface expression, (b) testing of platelet granule-
content secretion upon stimulation by different agonists and (c)
platelet granule content measurement. PSD was defined by (a)
reduced primary platelet granule secretion upon stimulation by at
least one of different platelet aggregation agonists (ADP, collagen,
U46619 and TRAP); (b) normal surface expression of GpIb/IX/V
and and GpIIb/IIIa and (c) normal platelet granule content
(serotonin, ATP, ADP, fibrinogen). Examinations were performed
on fresh samples on the same day of collection and a negative
control (i.e. a friend or non-consanguineous relative of the patient,
with no bleeding history, who accompanied the patient to the
hospital and agreed to be tested) was tested in parallel with patient
samples in each experiment. Platelet secretion was defined
defective when (a) testing results were below a normal range
established by secretion in up to 96 controls with no bleeding
history and (b) were below the levels measured for the control
sample that was tested with patient samples on the day of
examination. Patients were not tested for platelet secretion when
they were actively taking medications that may affect the results of
secretion testing; in this case, patients were requested to withdraw
medications and were tested after a washout period. Drugs that
were paid particular attention to were non-steroidal anti-inflam-
matory drugs, antiplatelet agents and serotonin reuptake inhibi-
tors. Blood samples were collected in 0.129 mol/L sodium citrate
and centrifuged at 150 g for 15 minutes to obtain platelet rich
plasma, which was used for the tests. Measurement of platelet
GpIb/IX/V and GpIIb/IIIa expression was performed by flow
cytometry as previously described [16]. Platelet secretion was
assessed by incubating samples of platelet rich plasma (0.45 mL)
with 50 mL of luciferin/luciferase reagent at 37uC for 30 seconds
and stirring at 1000 rpm in a lumiaggregometer (Lumi-aggrom-
eter, Chrono-log Corp). After incubation, 10 mL of one of the
agonist agents was added and ATP secretion and aggregation
tracings were recorded for 3 minutes [17]. Employed agonists were
adenosine diphosphate (ADP, Sigma-Aldrich Co., St. Louis, USA)
at 4 and 20 mM final concentrations, collagen (Mascia Brunelli,
Milano, Italy) at 2, 4 and 20 mg/mL final concentrations,
thrombin receptor-activating peptide (TRAP, Sigma-Aldrich
Co., St. Louis, USA) at 10 and 20 mM final concentrations and
the thromboxane A2 analogue, U46619 (Sigma-Aldrich Co., St.
Louis, USA), at 0.5 and 1 mM final concentrations. Normal ranges
(2.5th and the 97.5th percentiles of the distribution in controls) of
platelet secretion testing results were as follows (all expressed in
nmol of ATP/108 platelets): ADP 4 mM, 0.022–0.982 (number of
controls tested to establish range, n= 96); ADP 20 mM, 0.036–
0.612 (n= 59); collagen 2 mg/mL, 0.168–0.932 (n= 62); collagen
4 mg/mL, 0.216–1.260 (n= 68); collagen 20 mg/mL, 0.267–1.475
(n= 55); U46619 0.5 mM, 0.018–1.270 (n= 72); U46619 1 mM,
0.100–1.030 (n= 55); TRAP 10 mM, 0.012–1.074 (n= 41); TRAP
20 mM, 0.094–1.419 (n= 26). Measurement of intra-platelet
granule content was performed by the orto-phtaldialdehyde
method for serotonin, by the luciferine-luciferase method for
ADP and ATP, and by ELISA for fibrinogen [18]. The normal
range of values of platelet granule content was calculated by
measuring platelet content in 34 controls. Ranges (2.5th and the
97.5th percentiles of the distribution in controls) were as follows:
serotonin, 0.19–0.40 nmol/108 platelets; ADP, 1.30–2.88 nmol/
108 platelets; ATP, 3.17–7.07 nmol/108 platelets; ATP/ADP
ratio, 1.55–3.42; fibrinogen, 0.03–0.19 mg/109 platelets. All
patients included in the study and diagnosed with PSD tested
within the normal range for any of the aforementioned measure-
ments of platelet content.
Definition of clinical variables
Data on PSD patients were collected from digital and hard copy
clinical records. Information was retrieved on the following: age at
referral (i.e. age at the first clinical visit), age of the first bleeding
requiring medical attention, sex, region of residence, prevalence of
mucocutaneous bleeding symptoms (i.e. cutaneous bleeding,
epistaxis, bleeding from minor wounds or oral cavity bleeding),
bleeding following surgery, tooth extraction or peri-partum
hemorrhage, vaginal bleeding, muscular hematomas, hemarthrosis
or intracranial bleeding, BSS, age-normalized BSS (calculated
dividing BSS by the age at referral), presence of deficient secretion
upon stimulation by ADP, collagen, U46619 or TRAP at any
concentration or at the maximal dose, number of agonists eliciting
reduced response at any concentration or at maximal stimulation,
dose and pattern of deficient platelet secretion (i.e. the combina-
tion of agonists eliciting reduced response upon stimulation).
Information on the presence of medical conditions previously
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reported to be associated with PSD (reviewed by Fuse [1]) was
retrieved as well.
Study of the prevalence
Prevalence was calculated as the proportion of patient with PSD
on the total of patients belonging to the source population. The
source population was defined as the group of patients (a) referred
for diagnostic workup following a bleeding episode or for
hemostatic testing abnormalities in the same time period used
for patient inclusion (January 2008 and July 2011) and (b) found to
have clinical history of bleeding, with a BSS equal or above 4 at
clinical interview. While for analyses comparing patients with/
without associated conditions and those testing the association of
laboratory results with disease severity, we considered all PSD
patients recruited from January 2008 and March 2012 (n= 32), for
all the analyses investigating prevalence, we only considered PSD
patients recruited from January 2008 and July 2011 (n = 27).
Patients visited for the first time after July 2011 were excluded
from prevalence calculation. We indeed considered that many of
these patients still had to complete the diagnostic workup, hence
biasing the calculation of the prevalence of PSD towards an
underestimation.
In the group of patients who had BSS of 4 or more and were not
referred for platelet testing, prevalence was estimated using the
multiple imputation method. First, we constructed a logistic
regression model using data from patients with known PSD status,
with PSD status as dependent variable and age, sex and BSS score
as determinants. We obtained an equation of the probability of
PSD: log(y) = constant + age*Betaage + sex*Betasex + BSS*Be-
taBSS. We used the equation to calculate the probability of PSD for
each of the untested patients given their age, sex and BSS. We
calculated the estimated prevalence of the untested group as the
mean of all the individual probabilities. The final prevalence
estimation in the entire group of patients with bleeding history and
BSS of 4 or more was calculated as the weighted average of
prevalence estimations in the groups of patients who were tested
and that of patients who were not tested for platelet function (i.e.
imputed prevalence). Prevalence calculation was performed before
and after the exclusion of patients who only had ADP-induced
secretion defect (see main text). This was done in order to take into
account the possibility that secretion defect exclusive to the ADP
pathway may not be specific enough to define PSD.
Statistical analysis
Continuous variables were summarized by median value and
interquartile range (IQR), categorical values by percentages.
Prevalence was calculated as the proportion of patient with PSD
on the total of patients belonging to the source population defined
with the aforementioned criteria. The 95% confidence interval of
the prevalence was calculated according to Agresti-Coull [19].
The characteristics of groups of PSD patients with or without
accompanying clinical conditions were compared by calculating
differences in medians and proportions and computing their 95%
CI. Comparisons of non-dichotomous categorical variables were
carried out by Fisher’s exact test. Linear regression was used to
study the association between the number of agonists eliciting
reduced secretion and BSS, age-normalized BSS and age of first
bleeding requiring medical attention. The association between
laboratory results and clinical severity of PSD was assessed before
and after the exclusion of patients who only had ADP-induced
secretion defect (see above the rationale for this analysis). Kruskal-
Wallis test was used to study the aforementioned proxies of
bleeding severity across patients with different patterns of platelet
defect.
Ethics statement
The investigations were conducted in accordance with the
principle of the declaration of Helsinki. The study was approved
by the institutional review board of the Fondazione IRCCS Ca9
Granda – Ospedale Maggiore Policlinico (deliberation of February
21st, 2012) and participants gave their written informed consent.
Results
Patient characteristics and prevalence of disease
In the analyzed time period, 32 patients were diagnosed with
PSD. The characteristics of the patients included in the study are
presented in Table 1. Patients were more frequently of female sex,
had their first bleeding episode requiring medical attention during
young adulthood and had mild to moderate bleeding tendency, as
measured by BSS (Table 1). Reduced secretion upon stimulation
by ADP was the most frequent laboratory defect and defective
response to multiple agonists was a common occurrence (Table 1).
Of the 32 patients, 22 had no accompanying medical condition,
whereas for 10 patients PSD was associated with one or more
disease/medical condition. Associated medical conditions were
hepatitis C virus infection (with or without recent liver transplan-
tation surgery), autoimmune disease (a clinical history of immune
thrombocytopenic purpura with currently normal platelet counts
and rheumatoid arthritis) or neoplasm (myelodysplasia, Hodgkin’s
lymphoma, colorectal adenocarcinoma, urothelial carcinoma and
mammary sarcoma). Bleeding symptoms mainly consisted of
mucocutaneous bleeding (n= 29; 91%) or bleeding following
surgery, invasive medical procedures or delivery (n = 23; 72%).
Menometrorrhagia was frequent and occurred in two thirds of the
24 women (n= 16; 67%). Other spontaneous bleeding symptoms,
like muscle hemoatomas or hemarthrosis were rare (both occurred
in 2 patients, 6%). None of the patients had intracranial bleeding.
Of the 32 patients, 27 had their first visit in the period between
January 2008 and July 2011, so that they were used for the
calculation of the prevalence of PSD. Patients visited for the first
time after July 2011 (n= 5) were excluded from prevalence
calculation (see Methods section ‘‘Study of prevalence’’). The
workflow used for the calculation of prevalence is presented in
Figure 1. The prevalence of different diagnoses in 207 patients
with bleeding or abnormal coagulation and BSS above 4 is
presented in Table 2. In 145 patients who underwent diagnostic
screening (see Figure 1), the prevalence of PSD was 18.6%.
Multiple imputation in the 62 patients who were not tested for
platelet function yielded an estimated PSD prevalence of 19.3%.
The weighted mean of the two prevalences yielded a global
prevalence in the entire population with bleeding and BBS of 4 or
more of 18.8% (95% CI: 14.1–24.7%). Analysis of prevalence was
repeated after exclusion of patients with defects only upon
stimulation with ADP (see Methods section ‘‘Study of preva-
lence’’). This calculation yielded a prevalence of PSD with defects
to multiple platelet aggregation agonists of 13.5% (95% CI: 9.6–
21.2%). Details on the analysis are provided in Table S2.
Comparison of patients with or without associated
medical conditions
The characteristics of the 22 patients without associated medical
conditions and those of the 10 patients with associated medical
conditions are presented in Table S3. Patients without associated
conditions displayed younger age at first bleeding requiring
medical attention (patients without vs with associated conditions,
median age: 18 vs 45 years, difference: -27 years, 95% CI: -46 to -
9 years) and at study enrollment (median age: 34 vs 50 years,
difference: -16 years, 95% CI: -34 to 1 years). The distribution of
Prevalence and Characteristics of PSD
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the pattern of platelet defect (i.e. the type of agonist eliciting
reduced secretion) was different in the two groups (Fisher’s exact
test, P = 0.007). Single agonist defect was common in patients
without associated conditions, whereas patients with associated
conditions always had combined defects (prevalence of single-
agonist defect in patients without vs with associated conditions, 36
vs 0%, difference 36%, 95% CI: 4 to 57%).
Relationships between platelet testing results and
bleeding severity
We sought to determine whether the type and extension of
platelet defect was associated with proxies of bleeding severity.
The number of agonists eliciting reduced secretion at any
concentration or at maximal concentration of the agonist was
not associated with BSS, age-normalized BSS or age at first
bleeding requiring medical attention at linear regression analysis
(Table 3). The lack of association was observed both in an
unadjusted analysis and after adjusting for potential confounders
(Table 3). No association was found even after stratifying for the
presence of associated medical conditions or after excluding
patients with defect only upon stimulation with ADP (Tables S4,
S5 and S6). We plotted the pattern of platelet defect against BSS,
age-normalized BSS and age at first bleeding requiring medical
attention (Figure 2A–C). While the values of those proxies of
bleeding severity were clustered for some pattern of deficiency (e.g.
combined ADP, U46619 and TRAP deficiency), they were spread
on a wider range for other deficiencies (e.g. combined ADP,
collagen and TRAP deficiency). Overall, the median values of the
different proxies of bleeding severity were not different across
patterns of platelet defect (Figure 2A–C). No difference in the
median was observed also across patterns of platelet defect upon
Table 1. Demographic, clinical and laboratory characteristics in 32 patients with primary secretion defects.
Variable Value
Median age at referral, y (IQR) 35 (21–52)
Median age at first bleeding requiring medical attention, y (IQR) 28 (15–42)
Female sex, n (%) 24 (75)
Median bleeding severity score, points (IQR) 6.5 (5–10)
Median age-adjusted bleeding score, points/y (IQR) 0.17 (0.13–0.35)
Secretion defect upon stimulationa
ADP any concentration, n (%) 32 (100)
ADP 20 mM, n (%) 24 (75)
Collagen any concentration, n (%) 13 (41)
Collagen 20 mg/mL, n (%) 1 (3)
U46619 any concentration, n (%) 16 (50)
U46619 1 mM, n (%) 10 (31)
TRAP any concentration, n (%) 12 (38)
TRAP 20 mM, n (%) 3 (9)
Number of agonists with reduced response, n (%)
1 agonist 8 (25)
2 agonists 9 (28)
3 agonists 13 (41)
4 agonists 2 (6)
Number of agonists with reduced response at maximal stimulation, n (%)
0 agonists 7 (22)
1 agonist 13 (41)
2 agonists 11 (34)
3 agonists 1 (3)
Pattern of platelet defect, n (%)
ADP 8 (25)
ADP, TRAP 2 (6)
ADP, U46619 6 (19)
ADP, U46619, TRAP 3 (9)
ADP, collagen 1 (3)
ADP, collagen, TRAP 5 (16)
ADP, collagen, U46619 5 (16)
ADP, collagen, U46619, TRAP 2 (6)
a Number and percentage of patients showing reduced ATP secretion upon stimulation by the reported agonist at the reported concentration.
IQR, interquartile range; ADP, adenosine diphosphate; TRAP, thrombin receptor-activating peptide.
doi:10.1371/journal.pone.0060396.t001
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maximal agonist stimulation (pattern vs BSS, P= 0.342; pattern vs
age-normalized BSS, P= 0.585; pattern vs age at first bleeding
requiring medical attention, P= 0.132; all P-values calculated by
Kruskal-Wallis test). No association was found also when
investigating only groups of patients with or without accompany-
ing medical conditions (not shown).
Discussion
We collected information on patients referred to our center for
bleeding or hemostatic test abnormalities in the last three years in
order to study the prevalence, characteristics and determinants of
bleeding severity in patients with PSD. Findings of this study were
that (a) PSD is found in one fifth of patients with bleeding
diathesis; (b) patients with accompanying medical conditions had
different characteristics from those without such conditions; (c) the
type and extension of platelet defect was not associated with the
severity of bleeding.
The prevalence of PSD was found by Quiroga et al. to be 19%
in patients with mucocutaneous bleeding [10] and by Philipp to be
36% in women with menorrhagia [11]. However, in the 2010
World Federation of Hemophilia Global Survey (URL: http://
www1.wfh.org/publications/files/pdf-1427.pdf), the prevalence of
PSD in patients with bleeding from causes other than von
Willebrand disease and hemophilia is not taken into consideration.
Nonetheless, it is mentioned in the Survey that many countries
reported a high number of patients with ‘‘platelet defects other
than Glanzmann’s thrombasthenia and Bernard-Soulier syn-
drome’’. This underestimation probably reflects the incomplete
diffusion of platelet testing, required to identify PSD. In this study,
focusing the investigation on all patients with any bleeding
symptoms and BSS of 4 and above yielded a prevalence of
approximately 19%. Our study shows that the prevalence of these
defects is considerable also in patients with an important history of
bleeding, indicating the importance of PSD as a cause of clinically
relevant bleeding at the population level. These results warrant
interventions to make the diagnosis of PSD more widely available.
This entails the development and diffusion of assays that can be
more easily and rapidly performed. In consideration of the fact
that many patients with PSD bleed during surgery or other
invasive medical procedures, the detection of the defect at an early
age could prevent unnecessary bleeding episodes. Screening for
ADP-deficiency might be a sensitive strategy, given that ADP
deficiency was herein present in all investigated PSD patients, but
Figure 1. Flow-chart of the study of the prevalence of PSD.
doi:10.1371/journal.pone.0060396.g001
Table 2. Diagnosis and bleeding severity score values in 207 patients.
Diagnosis N (%) Age at diagnosis, median (IQR) BSS, median (IQR)
Coagulation factor deficiencya 27 (13) 37 (15–55) 6 (4–8)
von Willebrand disease 25 (12) 36 (22–4) 9 (6–12)
Primary secretion defects 27 (13) 35 (20–54) 6 (5–10)
Other platelet defectb 7 (3) 43 (32–54) 10 (4–15)
Defect in fibrinolysis 2 (1) 29, 38d 9, 10d
Secondaryc 8 (4) 56 (35–74) 7 (5–10)
Negative screening
Including platelet functional testing 49 (24) 41 (26–50) 6 (5–8)
Not tested for platelet function 62 (30) 41 (26–60) 5 (4–6)
Patients with clinical bleeding or coagulation abnormalities and bleeding severity score of 4 or more are presented.
aIncluding hemophilia A and B or rare bleeding disorders.
bIncludes d-storage pool deficiency and Glanzmanns thrombasthenia.
cSecondary to drugs or to underlying medical conditions.
dIndividual values are reported.
BSS, bleeding severity score.
doi:10.1371/journal.pone.0060396.t002
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specificity of the finding of PSD exclusive to stimulation with ADP
might be a concern.
Patients without associated medical conditions had earlier age of
first bleeding and different platelet functional defect pattern
compared to patients with PSD and accompanying medical
conditions. This suggests a possible different etiologic and
pathogenic mechanisms in the two groups of patients. The early
age of onset in patients without associated conditions indicates
congenital defects that may be amenable to genetic mapping.
There was no association, in patients with or without
accompanying conditions or in the entire group, between the
pattern and extension of platelet functional defect and proxies of
the severity of bleeding. One of the reasons for these negative
results might have been the tiny sample size of the study. However,
the firmly negative results and the complete lack of an association
suggest that the effect of platelet functional defect, if any, is likely
small. This result suggests that characterizing the type and
extension of platelet defect might provide little prognostic
information on the severity of bleeding, once a diagnosis of PSD
is established.
Our study has limitations. Platelet functional testing was not
performed in patients with BSS below 4, not enabling the
classification of patients with isolated or very mild bleeding with
respect to their PSD status. Although this might have blunted the
appreciation of the entire spectrum of the bleeding severity of
these conditions, it also restricted the analysis to those patients who
have clinically relevant disease. A number of patients were not
referred for platelet testing, possibly leading to inaccurate
prevalence estimation. To circumvent this limitation, we per-
formed multiple imputation to estimate the prevalence of PSD in
this subgroup of patients. However, the prevalence of PSD found
in this study was remarkably similar to that described by Quiroga
et al. in patients with mucocutaneous bleeding. Even after we
excluded all patients with defect only upon stimulation by ADP,
the estimate of PSD prevalence remained as high as 14%. These
findings indicate that the prevalence of PSD in patients with
bleeding remains considerable even when using conservative
criteria to define this condition. Because patients with thrombo-
cytopenia were not excluded from platelet functional testing, our
prevalence estimation might not be representative of the
prevalence of PSD in patients with thrombocytopenia. Another
possible limitation of the study is that BSS has been validated in
von Willebrand disease type 1 and 3 [12,13]. Its use in other
conditions characterized by mild bleeding tendency has been
highly recommended but it is still not validated [20,21]. Although
BSS was not the only proxy of diseases severity in our study, we
recognize that its application in a disease different from von
Willebrand disease might have partially limited our evaluation of
disease severity in patients with PSD. Nonetheless, we herein chose
to use BSS for a number of reasons. First, the same type of BSS
presented in this study has been successfully used in other bleeding
conditions different from the ones it was originally conceived for
[20–22]. BSS has been previously used in PSD and other
investigators have suggested its adoption for the assessment of
disease severity in PSD [23,24]. In addition, similarly to von
Willebrand disease, PSD is a defect of primary hemostasis,
Figure 2. Relationships between measures of bleeding severity
and pattern of platelet defect. The Figure shows the distribution of
bleeding severity score (top), age-normalized bleeding severity score
(middle) and age of first bleeding requiring medical attention (bottom)
in patients with different patterns of platelet defect. The asterisk (*)
indicates a patient with age-normalized bleeding severity score of 1.89.
P-values were calculated by Kruskal-Wallis test.
doi:10.1371/journal.pone.0060396.g002
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characterized by mild to moderate bleeding symptoms. Finally, a
limitation of the study is that sample size was relatively small.
However, we were able to collect a well-characterized cohort of
patients, in whom testing of platelet function was accurate and
complete. The patient number available for this study was
sufficient to have rather precise estimations of the prevalence of
these conditions. The study was also empowered to detect large
difference between study subgroup and strong, clinically-relevant
relationships between study measurements and bleeding severity.
In conclusion, PSD was found by this study to be present in
approximately one fifth of patients with bleeding diathesis. In
patients with PSD, the severity of bleeding manifestations was not
associated with the type and extension of the laboratory defect.
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